MedTrace Logo

Dermal Blood Flow Response to Escalating Doses of Histamine, Administered by a Skin Prick

NCT04399213 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-05-27

No results posted yet for this study

Summary

To determine the effective dose and the time course, the dermal blood flow response to histamine will be evaluated at different doses (5 µg, 15 µg and 50 µg). Histamine will be administered by a skin prick on the volar surface of subjects' forearm, alongside a negative control. Changes in dermal blood flow will be measured with laser Doppler imaging at different time points following the skin prick.

Conditions

Interventions

PROCEDURE

50 µg Histamine

Skin prick through 50 µg/5 µL histamine diHCl

PROCEDURE

15 µg Histamine

Skin prick through 15 µg/5 µL histamine diHCl

PROCEDURE

5 µg Histamine

Skin prick through 5 µg/5 µL histamine diHCl

PROCEDURE

Placebo (saline)

Skin prick through 5 µL saline (0.9% NaCl)

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2019-02-19
Completion
2019-02-19

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04399213 on ClinicalTrials.gov